Epacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037

被引：0
|
作者：
Hamid, O. [1 ]
Gajewski, T. F. [2 ,3 ]
Frankel, A. E. [4 ]
Bauer, T. M. [5 ]
Olszanski, A. J. [6 ]
Luke, J. J. [7 ]
Balmanoukian, A. S. [1 ]
Schmidt, E. V. [8 ]
Sharkey, B. [9 ]
Maleski, J. [9 ]
Jones, M. J. [9 ]
Gangadhar, T. C. [10 ]
机构：
[1] Angeles Clin & Res Inst, Res, Los Angeles, CA USA
[2] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Med, Sect Hematol Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA
[4] Univ Texas Southwestern Med Ctr Dallas, Internal Med, Dallas, TX 75390 USA
[5] Sarah Cannon Res Inst Tennessee Oncol, Drug Dev Unit, Nashville, TN USA
[6] Fox Chase Canc Ctr, Dept Med Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[7] Univ Chicago, Hematol Oncol, Chicago, IL 60637 USA
[8] Merck & Co Inc, Oncol Clin Res, Kenilworth, NJ USA
[9] Incyte Corp, Drug Dev, Wilmington, DE USA
[10] Univ Penn, Abramson Canc Ctr, Hematol Oncol Div, Med, Philadelphia, PA 19104 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1214O
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037
    Gangadhar, T. C.
    Hamid, O.
    Smith, D. C.
    Bauer, T. M.
    Wasser, J. S.
    Olszanski, A. J.
    Luke, J. J.
    Balmanoukian, A. S.
    Kaufman, D. R.
    Zhao, Y.
    Maleski, J.
    Jones, M. J.
    Leopold, L.
    Gajewski, T. F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037
    Gangadhar, Tara C.
    Schneider, Bryan J.
    Bauer, Todd Michael
    Wasser, Jeffrey S.
    Spira, Alexander I.
    Patel, Sandip P.
    Balmanoukian, Ani Sarkis
    Bauml, Joshua
    Schmidt, Emmett V.
    Zhao, Yufan
    Jones, Mark M.
    Tarhini, Ahmad A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Epacadostat Plus Pembrolizumab in Patients with Non-Small Cell Lung Cancer: Phase 1/2 Results from ECHO-202/KEYNOTE-037
    Villaruz, L.
    Schneider, B.
    Bauer, T.
    Spira, A.
    D'Amato, G.
    Wasser, J.
    Balmanoukian, A.
    Lara, P.
    Olszanski, A.
    Gajewski, T.
    Patel, S.
    Tarhini, A.
    Bauml, J.
    Schmidt, E.
    Bowman, J.
    Daniel, J.
    Owens, S.
    Mitchell, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S330 - S330
  • [4] Epacadostat plus pembrolizumab in patients with SCCHN: Preliminary phase VII results from ECHO-202/KEYNOTE-037.
    Hamid, Omid
    Bauer, Todd Michael
    Spira, Alexander I.
    Olszanski, Anthony J.
    Patel, Sandip Pravin
    Wasser, Jeffrey S.
    Smith, David C.
    Balmanoukian, Ani Sarkis
    Aggarwal, Charu
    Schmidt, Emmett V.
    Zhao, Yufan
    Gowda, Hema
    Gangadhar, Tara C.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037.
    Lara, Primo
    Bauer, Todd Michael
    Hamid, Omid
    Smith, David C.
    Gajewski, Thomas
    Gangadhar, Tara C.
    Somer, Bradley G.
    Schmidt, Emmett V.
    Zhao, Yufan
    Gowda, Hema
    Olszanski, Anthony J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
    Mitchell, Tara C.
    Hamid, Omid
    Smith, David C.
    Bauer, Todd M.
    Wasser, Jeffrey S.
    Olszanski, Anthony J.
    Luke, Jason J.
    Balmanoukian, Ani S.
    Schmidt, Emmett V.
    Zhao, Yufan
    Gong, Xiaohua
    Maleski, Janet
    Leopold, Lance
    Gajewski, Thomas F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (32) : 3223 - +
  • [7] Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.
    Smith, David C.
    Gajewski, Thomas
    Mid, Omid Ha
    Wasser, Jeffrey S.
    Olszanski, Anthony J.
    Patel, Sandip P.
    Mamtani, Ronac
    Schmidt, Emmett V.
    Zhao, Yufan
    Maleski, Janet E.
    Gangadhar, Tara C.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037.
    Hamid, Omid
    Bauer, Todd Michael
    Spira, Alexander I.
    Smith, David C.
    Olszanski, Anthony J.
    Tarhini, Ahmad A.
    Lara, Primo
    Gajewski, Thomas
    Wasser, Jeffrey S.
    Patel, Sandip P.
    Borges, Virginia F.
    Balmanoukian, Ani Sarkis
    Schmidt, Emmett V.
    Zhao, Yufan
    Jones, Mark M.
    Gangadhar, Tara C.
    Jones, Mark M.
    Gangadhar, Tara C.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Efficacy/safety of epacadostat plus pembrolizumab in triple-negative breast cancer and ovarian cancer: Phase I/II ECHO-202 study
    Spira, Alexander I.
    Hamid, Omid
    Bauer, Todd Michael
    Borges, Virginia F.
    Wasser, Jeffrey S.
    Smith, David C.
    Clark, Amy Sanders
    Schmidt, Emmett V.
    Zhao, Yufan
    Maleski, Janet E.
    Gangadhar, Tara C.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
    Cicin, Irfan
    Plimack, Elizabeth R.
    Gurney, Howard
    Leibowitz, Raya
    Alekseev, Boris Y.
    Parnis, Francis X.
    Peer, Avivit
    Necchi, Andrea
    Bellmunt, Joaquim
    Nishiyama, Hiroyuki
    Clark, Jason
    Munteanu, Mihaela
    Kataria, Ritesh
    Jia, Calvin
    Powles, Thomas
    Sternberg, Cora N.
    BMC CANCER, 2024, 23 (SUPPL 1)
12345